This is a Phase II open, randomized, active comparator-controlled multi center study in patients with severe type-1 diabetes. This is a two-armed study where patients are randomized in a 2:1 ratio between IBsolvMIR and heparin. Eighteen patients are planned to be included.
The study consists of up to 8 visits; screening, transplantation surgery with bolus administration of study drug or active comparator, IBsolvMIR doses on day 1, 3 and 6 after surgery, follow up visits on day 7 and 14, and follow-up phone call on day 44.
The primary endpoint is to study AEs up to 44 days following study drug administration. The secondary endpoints are to evaluate changes in TAT, C-peptide, C3a and HGF at baseline and during the first 24 hours after study drug administration, as well as evaluate a change in levels of C-peptide-glucose-creatinine ratio on day 14 compared to baseline.

Start Date08 Feb 2021

Sponsor / Collaborator

TikoMed AB

NCT03705390

/ TerminatedPhase 2IIT

A Phase II Pilot Single-arm Safety and Tolerability Study of ILB® in Patients With Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)

This is a phase II study to determine the safety and tolerability of ILB®, a type of low molecular weight dextran sulfate, in patients with Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS)

Start Date29 Mar 2019

Sponsor / Collaborator

University of Birmingham

[+3]

NCT03613571

/ TerminatedPhase 2

A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis

This is a Phase 2a single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis (ALS) of intermediate progression rate. Eligible subjects will be administered weekly doses of ILB. A total of 5 subcutaneous (s.c.) doses will be administered at the study clinic.
The study consists of 10 visits; One 2-part screening visit, 5 ILB administration visits, and 3 follow-up visits. Each individual patient's study participation will be 4 months, including the screening and follow-up visits. Fifteen patients are planned to be included.
The primary objective of the study is to evaluate the safety and tolerability of ILB in patients diagnosed with ALS.
ILB is a solution for subcutaneous (s.c.) injection in saline solution. The dose administered will depend on the subject's body weight at the second study visit, prior to the first ILB administration.
No formal sample size calculation has been performed for this study. The proposed sample size is considered sufficient in this early phase 2 development to provide adequate information on the patients. Categorical data will be presented as counts and percentages. Continuous data will be summarised using descriptive statistics.

Start Date15 Aug 2018

Sponsor / Collaborator

TikoMed AB

100 Clinical Results associated with Dextran sulfate sodium(TikoMed AB)

100 Translational Medicine associated with Dextran sulfate sodium(TikoMed AB)

100 Patents (Medical) associated with Dextran sulfate sodium(TikoMed AB)

2,297

Literatures (Medical) associated with Dextran sulfate sodium(TikoMed AB)

01 Aug 2025·BIOMEDICINE & PHARMACOTHERAPY

Propionate suppresses colitis-associated colorectal cancer in mice by Or51e2

Article

Author: Hong, SungHoi ; Kim, Ji-Sun ; Choi, Jung-Won ; Lee, InRyeong ; Shin, Min-Jeong ; Lee, Sung-Joon ; Lee, Ha Lim ; Yoon, Ye Eun ; Kim, Yeonji ; Jeong, Mi-Young ; Chi, Sung-Gil

Dietary fiber intake is associated with a reduced risk of colorectal cancer (CRC), partly through the microbial fermentation of fiber into short-chain fatty acids (SCFAs). Among these, propionate binds to olfactory receptor 51E2 (Or51e2), which is ectopically expressed in the colon, but its role in CRC remains unclear. In this study, we evaluated Or51e2 expression in murine CT26 CRC cells and mouse colon tissues. Intracellular cAMP levels and CRE-luciferase activity were measured in CT26 and Or51e2-transfected Hana3A cells. The effects of propionate on proliferation, apoptosis, and MEK/ERK signaling were examined in CT26 cells. In vivo, a colitis-associated CRC model was established in wild-type (WT) and Or51e2-knockout (Or51e2 KO) mice using azoxymethane and dextran sulfate sodium (AOM/DSS). Propionate was administered intraperitoneally, and tumor burden, colon length, polyp number, histological changes, and MEK/ERK phosphorylation were assessed. Or51e2 expression was higher than other SCFA receptors in both CT26 cells and mouse colon tissues. Propionate treatment increased intracellular cAMP, activated CRE-luciferase, inhibited cell proliferation, induced apoptosis, and suppressed MEK/ERK phosphorylation in an Or51e2-dependent manner. In vivo, propionate reduced tumor growth, polyp formation, and MEK/ERK activation in WT mice, but not in Or51e2 KO mice. These findings suggest that Or51e2 mediates the anti-tumor effects of propionate through modulation of cAMP and MEK/ERK signaling, supporting its potential as a therapeutic strategy for CRC treatment.

01 Jul 2025·CANCER LETTERS

Intestinal estrogen receptor beta modulates the murine colon tumor immune microenvironment

Article

Author: Kutter, Claudia ; Gallardo-Dodd, Carlos J ; Williams, Cecilia ; Chen, Baizhen ; Birgersson, Madeleine ; Holm, Matilda ; Hases, Linnea ; Archer, Amena ; Stepanauskaitė, Lina

Chronic inflammation contributes to the development of colorectal cancer, partly through its regulation of the microenvironment and antitumor immunity. Interestingly, women have a lower incidence of colorectal cancer, and estrogen treatment has been shown to reduce the occurrence of colorectal tumors. While intestinal estrogen receptor beta (ERβ, Esr2) can protect against colitis and colitis-induced cancer in mice, its role in shaping the tumor microenvironment remains unknown. In this study, we performed RNA sequencing to analyze the transcriptome of colonic epithelia and tumors from azoxymethane/dextran sulfate sodium-treated wild-type and intestinal ERβ knockout (ERβKO^Vil) mice and vehicle-treated controls. This revealed significant differences in gene expression and enriched biological processes influenced by sex and genotype, with immune-related responses being overrepresented. Deconvolution supported differential immune cell abundance and immunostaining showed that tumors from ERβKO^Vil mice displayed significantly increased macrophage infiltration, decreased T cell infiltration, and impaired natural killer cell infiltration. Further, ERβ mRNA levels in clinical colorectal tumors correlated with immune signaling profiles and better survival. Our findings indicate that intestinal ERβ promotes an antitumor microenvironment and could potentially affect the effectiveness of immunotherapy. These insights highlight the importance of ERβ in modulating antitumor immunity and underscore its therapeutic potential in colorectal cancer.

01 Jul 2025·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Dysbiosis of the gut micro-flora aggravates symptoms and accelerates disease progression in MASLD-IBD Co-morbid mice through host-microbial metabolic imbalance

Article

Author: Liu, Yi ; Chen, Jun ; Huang, Ruiting ; Lin, Minling ; Qiu, Yongyi ; Peng, Hui ; Chen, Lei ; Li, Wanyu

Studies have shown that dysregulation of intestinal microbial structure and co-metabolic imbalance caused by diet and other factors play important role in MASLD and IBD. However, it is unclear how host-microbial interactions differ in the two diseases, and what potential impact they have on accelerating disease progression. Our study aims to find the disease characteristics in MASLD, IBD and their complication from the perspective of host-microbial metabolism. In our study, mouse models of MASLD, IBD, and MASLD-IBD induced by high-fat diet and dextran sulfate sodium. Detecting the pathological changes of colon and liver. Using 16s rRNA to screen out specific micro-flora, and UPLC-MS to monitor the changes of metabolites in feces. The micro-flora-metabolite co-expression network was constructed by Cytoscape software. The result showed that MASLD-IBD mice aggravate intestinal barrier damage, hepatic steatosis and fibrosis, immune inflammation and other pathological changes. In MASLD-IBD mice, the structural change of gut micro-flora is similar to IBD mice, which significantly reduced the abundance of Actinobacteriota, Desulfobacterota while increasing the abundance of Proteobacteria, and the metabolic disorder include nine metabolic pathways, such as tryptophan, bile acids and short-chain fatty acids, is similar to MASLD mice. Their co-expression network indicates that different specific micro-flora are closely related to the metabolic disorder and disease symptoms of MASLD-IBD mice. Analyzing the relationship between intestinal microbial dysregulation and hoetic co-metabolic imbalance is helpful to understand the mechanism of MASLD and IBD comorbidity, which suggesting that combined liver-gut therapy may be a new method for the treatment of MASLD-IBD complication.

News (Medical) associated with Dextran sulfate sodium(TikoMed AB)

28 Apr 2023

·www.globenewswire.com

Polydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business Combination

Polydex Pharmaceuticals Limited (OTC Pink: POLXF) (the “Company” or “Polydex”) announced today that it has entered into a Plan of Arrangement agreement (the “Arrangement Agreement”) whereby BioSpectra, Inc. and BioSpectra Canada, Ltd (together, “BioSpectra”) will acquire all of the outstanding common and preferred shares of the Company for total consideration of $6,940,000, of which US$6,924,980.02 will be paid for 3,432,478 common shares outstanding and US$15,019.98 will be paid for 899,400 Class B Preferred shares outstanding. The price per common share is US$2.017. Under the Arrangement Agreement the transaction will be effected pursuant to a statutory plan of arrangement (the “Arrangement”) under section 182 of the Ontario Business Corporations Act (the “OBCA”). The Arrangement will result in each issued and outstanding share of Polydex being deemed transferred to BioSpectra by each Polydex shareholder, without any further act or formality on the part of the Polydex shareholder, and each Polydex shareholder shall receive the Consideration in exchange for their shares. The Board of Directors of the Company has received a fairness opinion from Evans & Evans, Inc., an independent consultant that provides business valuations. The fairness opinion supports the terms of the Arrangement and the Consideration as fair to the Company’s shareholders. The Board has approved the Arrangement and the Arrangement Agreement. The Company will seek an interim order approving the deal from the Ontario Court of Justice. Following receipt of a favorable interim order, the Company will call a meeting of shareholders to obtain shareholder approval. Shareholders will receive a Notice of Meeting and Information Circular prior to such meeting. The Board of the Company unanimously recommends approval of the transaction. If the Arrangement is approved by shareholders at the shareholder meeting, the Company will then seek a final order from the Ontario Court of Justice approving the Arrangement and authorizing its closing. George Usher, the President and CEO of Polydex commented that “We are extremely pleased with the transaction we have struck with BioSpectra. This transaction comes as a conclusion to a long process undertaken by the Board to enhance shareholder value. We have studied multiple options and believe this is the best one for our shareholders.” Polydex, based in Toronto, Ontario, is engaged in the manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry and also the development, manufacturing and marketing of biotechnology-based products for the human pharmaceutical market. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The Company conducts its business operations through its two wholly-owned subsidiaries/divisions. The manufacture and sale of Dextran and derivative products is conducted through Dextran Products and Chemdex Inc. which is incorporated in the State of Kansas, United States. The content above comes from the network. if any infringement, please contact us to modify.

13 Sep 2022

·www.prnewswire.com

TikoMed's ILB® inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro

Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candidate ILB® to: inhibit infection of human cells by the NL63 coronavirus assessed by immunofluorescence of viral particles; and directly block the interaction of the SARS-CoV-2 viral spike protein with the ACE2 receptor; and modulate the downstream consequences of viral infection including the reactive cytokine release from human microglia induced by various SARS-CoV-2 variant spike proteins. The study shows that ILB® blocked ACE2:spike protein interaction and inhibited coronaviral infection. ILB® also attenuated the omicron-induced release of pro-inflammatory cytokines, including TNFa, from human microglia, indicating control of post-viral neuroinflammation. "This work extends our findings of ILB®'s antiviral impact upon flavivirus infections to now include coronavirus. Furthermore, we are excited to have uncovered a potential molecular mechanism for these findings by showing that ILB® inhibited SARS-CoV-2 spike protein interacting with ACE2, the key docking site for SARS-CoV-2 to gain entry to human cells," said Professor Ann Logan PhD (Professor of Regenerative Medicine & CSO, Axolotl Ltd). Professor Nicholas Barnes PhD PBPhS (Professor of Pharmacology & CEO, Celentyx Ltd) also commented: "In pathological post-viral fatigue syndromes such as long COVID, a key brain cell called microglia appear overactive and promote the associated neuroinflammation. This data showed that activated microglia are calmed by ILB® in vitro and suggests ILB® has the potential to inhibit neuroinflammation and hence improve symptoms of patients with conditions such as long COVID." TikoMed recently announced the publication of a peer-reviewed article on the mode of action of ILB®. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases. ILB® both mobilized and modulated naturally occurring tissue repair mechanisms, released heparin-binding growth factors, and restored cellular homeostasis and function, . Additionally, TikoMed has reported that ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, . Media: International: Richard Hayhurst [email protected] or +44 7711 821527 Nordics: Ola Bjorkman [email protected] or +46 70 245 7497 About Corona viruses Coronaviruses are a large family of enveloped, positive-stranded RNA pathogenic viruses that cause infectious disease in animals and humans. For example, the highly transmissible SARS-CoV-2 virus causes coronavirus disease (COVID-19) which causes a mild to moderate respiratory disease in most humans, but susceptible individuals can become dangerously ill, developing severe acute respiratory syndrome (SARS) and acute respiratory distress syndrome (ARDS) that can result in organ damage[1]. The global pandemic of COVID-19 disease that has spread since 2019 has had devastating health, social and economic consequences that remain burdensome[2]. By August 2022 that World Health Organisation report 599,825,400 confirmed cases of COVID19 and 6,469,458 confirmed deaths (), representing just over 1% of those infected. *bioRxiv is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals. For full study details on "A clinical stage LMW-DS drug inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia," please access the publication: . [1]Mistry P, Barmania F, Mellet J, Peta K, Strydom A, Viljoen IM, James W, Gordon S, Pepper MS. SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front Immunol. 2022 Jan 3;12:809244. doi: 10.3389/fimmu.2021.809244. PMID: 35046961; PMCID: PMC8761766. [2]Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2. Science. 2022 Mar 11;375(6585):1116-1121. doi: 10.1126/science.abm4915. Epub 2022 Mar 10. PMID: 35271324; PMCID: PMC9009722 CONTACT: Contact: [email protected] or +46 42 23 84 40 This information was brought to you by Cision SOURCE Tikomed

Vaccine

07 Sep 2022

·www.prnewswire.com

TikoMed's drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action

VIKEN, Sweden, Sept. 7, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company's lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African and Asian) and Yellow Fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral particles. In the study, ILB® potently inhibited infection by all the strains of Dengue, Zika and Yellow Fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 μg/ml. Professor Nicholas Barnes PhD PBPhS (Professor of Pharmacology & CEO, Celentyx Ltd, and one of the world's most highly cited researchers ) commented: "It is well recognised that infection by flaviviruses like Dengue, Zika and Yellow Fever virus can lead to catastrophic life-threatening conditions. This emphasises the clinical need for safe and effective medicines to treat these infections. What I find particularly exciting about these results is the effects observed at ILB® concentrations that have been achieved in humans following doses that have been well tolerated. These findings offer hope to the millions of patients that continue to be devastated by flavivirus infections." TikoMed recently announced the publication of a peer-reviewed, scientific article on the mode of action of ILB®. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases. ILB® both mobilized and modulated naturally occurring tissue repair mechanisms, released heparin-binding growth factors, and restored cellular homeostasis and function. "These results provide further evidence of the anti-viral potential and unique broad spectrum mechanism of action of TikoMed's ILB® drug platform. We have already initiated clinical development programs for Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation and plan to consider additional evaluation in other diseases," said Anders Kristensson, CEO of TikoMed. *bioRxiv is a free online archive and distribution service for unpublished preprints in the life sciences. It is operated by Cold Spring Harbor Laboratory, a not-for-profit research and educational institution. By posting preprints on bioRxiv, authors are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals. For full study details on "A clinical stage LMW-DS drug inhibits infection of human cells by Dengue, Zika and Yellow Fever viruses", please access the publication: . About flaviviruses Flaviviruses are responsible for the most abundant arboviral diseases of humans in terms of geographical distribution, morbidity and mortality; at least 2.5 billion people are at risk with, for example, an estimated 100-400 million Dengue infections a year. However, for infections by Dengue, Zika or Yellow Fever virus there are no effective anti-infective drug treatments nor for Dengue or Zika virus a safe effective vaccine and prevention at present focusses on vector (mosquito) control. Whilst symptoms from Dengue, Zika and Yellow Fever virus infection may be mild for some, they are very serious and life threatening for others. For instance, severe Dengue is a leading cause of hospitalisation and death among children and adults in Asian and Latin American countries. Likewise, Zika infection can have catastrophic consequences for pregnant women following the passing of the virus to their foetus with arising miscarriage or birth defects including microcephaly that can be fatal. CONTACT: Contact: [email protected] or +46 42 23 84 40 Media: International: Richard Hayhurst [email protected] or +44 7711 821527 Nordics: Ola Bjorkman [email protected] or +46 70 245 7497 This information was brought to you by Cision SOURCE Tikomed

Vaccine

100 Deals associated with Dextran sulfate sodium(TikoMed AB)

External Link

KEGG	Wiki	ATC	Drug Bank
D02047	-	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatitis, Chronic	Phase 2	Sweden	TikoMed AB	15 Jul 2022
Diabetes Mellitus, Type 1	Phase 2	Netherlands	TikoMed AB	08 Feb 2021
Diabetes Mellitus, Type 1	Phase 2	Norway	TikoMed AB	08 Feb 2021
Diabetes Mellitus, Type 1	Phase 2	Sweden	TikoMed AB	08 Feb 2021
Amyotrophic Lateral Sclerosis	Phase 2	Sweden	TikoMed AB	15 Aug 2018
Rejection of pancreas transplant	Phase 2	Sweden	-	04 Mar 2009
Hematologic Neoplasms	Phase 1	-	University of Uppsala	-
Stem cell mobilisation	Phase 1	Sweden	TikoMed AB	-
Brain Injuries, Traumatic	Preclinical	Sweden	TikoMed AB	-
Glaucoma	Preclinical	Sweden	TikoMed AB	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NIH P01DK043785 (ARVO2010)	Not Applicable	Inflammation	-	Dextran Sodium Sulfate (Control mice)	jmkrhznxqp(kqegnjgwki) = nvkminegyf yfmuxvjgaz (hkyaxrahjx )	Positive	01 Apr 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dextran sulfate sodium(TikoMed AB)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation